{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T15:46:53Z","timestamp":1782748013237,"version":"3.54.5"},"reference-count":46,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp;amp; Rheumatology"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Our study objective was to identify serum protein signatures associated with progression to rheumatoid arthritis (RA) and response to abatacept in at\u2010risk individuals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 440 serum samples from 118 APIPPRA (Arthritis Prevention In the Preclinical Phase of RA with Abatacept) study participants were selected from baseline to RA onset for 46 progressors of RA or to study end for 72 participants who did not develop RA. Samples were analyzed using the SomaScan 7k assay platform. Differential expression analysis was assessed by progression to RA (three pre\u2010RA time intervals to RA, progressors of RA vs nonprogressors, baseline to RA), and by treatment allocation (abatacept vs placebo). Risk and response signatures were identified in the full 7k panel and two prespecified subpanels defined as Inflammatory Mediators and Adaptive Immune Cell panel.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We observed significant changes in 80 proteins (68 down\u2010regulated and 12 up\u2010regulated) occurring between RA onset and 6 to 24 months before developing disease. Progression to RA was associated with increased levels of acute\u2010phase reactants SAA1 and SAA2 and reductions in CTLA4, when compared to nonprogressors at the end of treatment. Two up\u2010regulated proteins (CTLA4 and CD86) and seven down\u2010regulated proteins (CXCL13, FCRL4, FCER2, CCL21, LTA|LTB, FDCSP, and IL22RA2) were observed in participants receiving abatacept compared to placebo regardless of RA outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Protein signatures dominated by acute\u2010phase proteins define progression to RA, whereas changes associated with abatacept therapy highlight potential mechanisms of treatment response. Such signatures provide a better understanding of the immune landscape of the at\u2010risk phase, opening up the possibility of new treatment modalities for RA prevention.<\/jats:p>\n                    <jats:p>\n                      <jats:boxed-text content-type=\"graphic\" position=\"anchor\">\n                        <jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" mimetype=\"image\/png\" position=\"anchor\" specific-use=\"enlarged-web-image\" xlink:href=\"graphic\/art70082-gra-0001-m.png\">\n                          <jats:alt-text>image<\/jats:alt-text>\n                        <\/jats:graphic>\n                      <\/jats:boxed-text>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.70082","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T09:14:54Z","timestamp":1770628494000},"page":"1403-1413","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Serum Proteomic Signatures of Rheumatoid Arthritis Risk and Response: Analysis of a Rheumatoid Arthritis Interception Trial"],"prefix":"10.1002","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3080-8396","authenticated-orcid":false,"given":"Marianna","family":"Jasenecova","sequence":"first","affiliation":[{"name":"Centre for Rheumatic Diseases King's College London  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Coyle","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases King's College London  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6742-6315","authenticated-orcid":false,"given":"Alina","family":"Mihalovits","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases King's College London  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Ryan","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases King's College London  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Pook","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases King's College London  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esperanza","family":"Perucha","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases King's College London  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Harker","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases King's College London  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melody","family":"Chin","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases King's College London  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1714-9963","authenticated-orcid":false,"given":"Sam","family":"Norton","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases King's College London  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Cope","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases King's College London  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202127"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex340"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.824501"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01193-X"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.01.042"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.7326\/M23-0272"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.01.021"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02650-8"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02649-1"},{"issue":"9","key":"e_1_2_7_11_1","article-title":"Hydroxychloroquine does not prevent the future development of rheumatoid arthritis in a population with baseline high levels of antibodies to citrullinated protein antigens and absence of inflammatory arthritis: interim analysis of the StopRA trial [abstract]. Abstract presented at: ACR Convergence 2022; November 10\u201314, 2022; Philadelphia, PA","volume":"74","author":"Deane KD","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"e_1_2_7_12_1","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001591","article-title":"Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trial","volume":"7","author":"Boheemen L","year":"2021","journal-title":"RMD Open"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212763"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.105767"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.43366"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2023-0334"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-2102-9"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217066"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224211"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/00045632241285843"},{"key":"e_1_2_7_21_1","unstructured":"SomaScan Assay.SomaLogic.2025.https:\/\/www.somalogic.com\/"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-3403-7"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"key":"e_1_2_7_24_1","volume-title":"SomaScan Assay v4.1: Technical note SL00000572 Rev 4: 2023\u201003","author":"SomaLogic","year":"2023"},{"key":"e_1_2_7_25_1","volume-title":"R: A Language and Environment for Statistical Computing","year":"2023"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517-6161.1995.tb02031.x"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevImmunol.v32.i4.40"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0338"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.42.6.665"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2006.05.011"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-00529-z"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.4110\/in.2024.24.e8"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41483"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200838415"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkae1010"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/697832"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2003-1313"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.12.012"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12858"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/febs.15327"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/cei\/uxab021"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.49"},{"key":"e_1_2_7_43_1","volume-title":"Immunobiology: The Immune System in Health and Disease","author":"Janeway CAJ","year":"2001"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20192195"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.11.040193.001203"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2007.01289.x"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0744-z"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.70082","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/art.70082","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.70082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T15:25:01Z","timestamp":1782746701000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.70082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1002\/art.70082"],"URL":"https:\/\/doi.org\/10.1002\/art.70082","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"2025-10-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}